SpecificIT | SpecificiT Pharma Inc.
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-2,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

About SpecificiT Pharma Inc.

SpecificiT Pharma Inc., a privately held biopharmaceutical company focuses on developing cellular therapies for hematological cancers that are currently untreatable with chimeric antigen receptor modified T cells (CAR-T) therapies.

The company’s unique approach directs unmodified donor T-cells at Minor Histocompatibility Antigens (“MiHAs”) to safely eliminate cancer cells in patients. In addition, the company is employing a proprietary platform to discover novel tumor neoantigens that would allow this unique immunotherapy approach to be used against solid tumors.